GlassScriptPhysician profile
Michael J Sperling
NPI 1518222108
$505.93
in general payments reported to CMS, 2019-2025
13 companies · $428 in 2025
The $428 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.21 · 2022: $19.46 · 2023: $24.58 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.71 | 2025 | Xifaxan |
| Novo Nordisk INC | $84.17 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $44.04 | 2022-2023 | Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.70 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $36.12 | 2025 | Airsupra |
| Abbvie INC. | $34.67 | 2025 | |
| Astellas Pharma US INC | $34.21 | 2021 | |
| Evofem Biosciences, INC. | $32.89 | 2025 | Solosec, Phexx, Phexxi |
| Exact Sciences Corporation | $22.50 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $20.11 | 2025 | Closurefast |
| Kowa Pharmaceuticals America, INC. | $16.78 | 2025 | Zoryve |
| Pfizer INC. | $16.07 | 2025 | |
| Sumitomo Pharma America, INC. | $15.96 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sperling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.